Related Experiment Videos
Muzolimine in advanced chronic renal failure
Zeitschrift Fur Kardiologie
|January 1, 1985
Summary
Muzolimine effectively treated edema and hypertension in patients with severe chronic renal failure. This diuretic demonstrated safety and efficacy for short-term use, improving metabolic acidosis without adverse effects.
Area of Science:
- Nephrology
- Pharmacology
- Internal Medicine
Background:
- Severe chronic renal failure (CRF) presents challenges in fluid and electrolyte management.
- Edema and hypertension are common complications in patients with advanced kidney disease.
Purpose of the Study:
- To evaluate the efficacy and safety of muzolimine in patients with severe chronic renal failure.
- To assess the drug's impact on hyperhydration, edema, hypertension, and metabolic acidosis.
Main Methods:
- A study involving 27 patients with creatinine clearances between 20 and 2 ml/min.
- Daily administration of muzolimine at 6.9 mg/kg for 10 to 25 days.
- Monitoring of fluid status, blood pressure, and metabolic parameters.
Main Results:
- Gradual decrease in hyperhydration and edema in all patients without hypotension.
- Beneficial effects on hypertension, particularly in patients with extracellular fluid expansion.
- Enhanced antihypertensive effects when combined with clonidine or minoxidil.
- Significant diuretic and natriuretic effects observed.
- Improvement in metabolic acidosis.
- No subjective adverse reactions or side effects reported.
Conclusions:
- High-dose muzolimine is an effective and safe option for short-term treatment in severe chronic renal failure.
- Muzolimine addresses key complications like edema, hypertension, and metabolic acidosis.
- The drug shows potential for managing fluid overload and improving blood pressure control in this patient population.